F60.3 F43.1
Conditions
Interventions
Group 1: Observational study: patients suffering from borderline disorder with and without comorbid posttraumatic disorder with or without naltrexone treatment
During treatment, we will conduct the „
Garbutt et al., 2009
Kampov-Polevoy et al., 1999) as well as the Qb-Atest (FDA approved
www.qbtech.com) – shortly after the admission. Moreover, patients will be asked to answer several questionnaires with respect to severity of the illness (with respect to severity and frequency of diss
Sponsors
Zentralinstitut für Seelische Gesundheit
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: - Patients suffering from borderline personality disorder and/or - posttraumatic stress disorder -German-speaking -Capacity to provide informed consent -Written Informed Consent -negative breath analysis for alcohol
Exclusion criteria
Exclusion criteria: - comorbid substance use disorder - non German-speaking - lack of capacity to provide informed consent - lack of written informed consent - blindness -neurological deficits influencing the eye-tracking - e.g. no smell or taste
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The aim of the study is to identify clinical phenotypes and parameters to deepen the biological underpinnings of borderline disorder (focusing the opioidergic and dopaminergic system) as well as to predict treatment response to naltrexone in borderline disorder with and without comorbid posttraumatic disorder | — |
Countries
Germany
Contacts
Public ContactMalte Bumb
Zentralinstitut für Seelische Gesundheit
Outcome results
None listed